Clinical trial Recruiting at 1 site Interventional Ages 30 to 80

Intensive versus standard care and education for cholesterol management in people with hypertension and diabetes

Official title: Comparison of Intensive Versus Standard Care & Education for Dyslipidemia in Hypertension and Diabetes Patients

Run by Saint Vincent's Hospital, Korea · NCT07045623 · Data updated 2026-11-12

This project will test whether a structured, intensive dyslipidemia management and education program helps adults with hypertension and diabetes improve their blood lipid levels.

More Hypertension trials

Quick facts

Study typeInterventional
Ages30 Years to 80 Years
SexAll
Enrollment348 (estimated)
SponsorSaint Vincent's Hospital, Korea
Academic / other
Locations1 site (Gyeonggi-do, Suwon-si)
StatusRecruiting
StartedApril 1, 2025
Main results expectedDecember 31, 2025
Study endsJune 30, 2026
Registry record updatedJuly 1, 2025
Trial IDNCT07045623 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 30–80 who are registered with the Hanam City Hypertension and Diabetes Program, have hypertension and diabetes, and can give written informed consent.

Probably not a fit

Patients with advanced kidney disease (eGFR <30), severe liver disease or cirrhosis, recent acute coronary syndrome within 6 months, pregnant or breastfeeding women, or those with psychiatric disorders interfering with participation are unlikely to benefit or are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults aged 30–80 who are registered in the Hanam City Hypertension and Diabetes Program will be assigned to receive either a centralized intensive dyslipidemia management and education program or usual/standard care. The intensive arm uses structured education, lifestyle counseling, and coordinated management to reinforce medication adherence and lifestyle changes. Primary outcomes focus on changes in blood lipid profiles, while secondary outcomes include quality of life, health behaviors, and treatment adherence. Results will inform whether a standardized intensive program is practical and effective in a primary-care affiliated education center.

Why it matters

Potential benefit: If successful, this approach could help patients achieve better cholesterol control, improve adherence and lifestyle habits, and lower long-term cardiovascular risk.

How similar studies have gone: Previous research has shown that intensive lipid management and education can improve lipid profiles and reduce cardiovascular events, though standardized programs in primary-care settings are less well validated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients registered in the Hanam City Hypertension and Diabetes Program
* Adults aged 30 to 80 years
* Individuals who have provided written informed consent to participate in the study

Exclusion Criteria:

* Chronic kidney disease stage 4 or higher (eGFR \<30 mL/min/1.73m²)
* Patients with liver cirrhosis or severe liver disease
* Patients with a history of acute coronary syndrome within the past 6 months
* Pregnant or breastfeeding women • Individuals with psychiatric disorders that may affect study participation

Where it's running

  • Catholic University of Korea, ST. Vincent's Hospital.
    Gyeonggi-do, Suwon-si, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.